If you have been reading about HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
is the just detectable difference in m/z, at that particular m/z, usually measured measured in milli mass units (mDa). In particular, the resolution may be different at different m/z. It is usually operationalized as the full width at half maximum a peak at that given m/z. The resolution is the ratio
== Further reading == Appanna, Varun P.; Auger, Christopher; Thomas, Sean C.; Omri, Abdelwahab (13 June 2014). "Fumarate metabolism and ATP production in Pseudomonas fluorescens exposed to nitrosative stress". Antonie van Leeuwenhoek. 106 (3): 431–438. doi:10.1007/s10482-014-0211-7. PMID 24923559. S2CID 1124142. Cabrefiga, J.; Frances, J.; Montesinos, E.; Bonaterra, A. (1 October 2014). "Improvement of a dry formulation of Pseudomonas fluorescens EPS62e for fire blight disease biocontrol by combination of culture osmoadaptation with a freeze-drying lyoprotectant". Journal of Applied Microbiology. 117 (4): 1122–1131. doi:10.1111/jam.12582. PMID 24947806.
== Selected publications == Moloney, P. J. (1926). "The preparation and testing of diphtheria toxoid (Anatoxine-Ramon)". American Journal of Public Health. 16 (12): 1208–1210. doi:10.2105/AJPH.16.12.1208. PMC 1321494. PMID 18012024. Moloney, P. J.; Fraser, C. J. (1927). "Immunization with diphtheria toxoid (anatoxine Ramon)". American Journal of Public Health. 17 (10): 1027–1030. doi:10.2105/AJPH.17.10.1027. PMC 1321911. PMID 18012293. Taylor, E. M.; Moloney, P. J. (1939). "A New Schick-Toxin". The Journal of Immunology. 37 (3): 223–232. doi:10.4049/jimmunol.37.3.223. S2CID 86572393. Fitzgerald, J. G.; Defries, R. D.; Fraser, D. T.; Moloney, P. J.; McKinnon, N. E. (1932). "Experiences with Diphtheria Toxoid in Canada". American Journal of Public Health and the Nation's Health. 22 (1): 25–28. doi:10.2105/ajph.22.1.25. PMC 1556712. PMID 18013424. Moloney, P. J.; Hennessy, J. N. (1942). "Purification of tetanus toxoid". The Biochemical Journal. 36 (7–9): 544–547. doi:10.1042/bj0360544. PMC 1266838. PMID 16747558. Moloney, P. J.; Hennessy, Joan N. (1944). "Titration of Tetanal Toxins and Toxoids by Flocculation". The Journal of Immunology. 48 (6): 345–354. doi:10.4049/jimmunol.48.6.345. S2CID 88201977. Moloney, P. J.; Coval, M. (1955). "Antigenicity of insulin: Diabetes induced by specific antibodies". The Biochemical Journal. 59 (2): 179–185. doi:10.1042/bj0590179. PMC 1216116. PMID 14351177. Moloney, P. J.; Goldsmith, L. (1957). "On the Antigenicity of Insulin". Canadian Journal of Biochemistry and Physiology. 35 (1): 79–92. doi:10.1139/y57-011. PMID 13396665.
Cleavage of fusion protein so that the fusion partner and protein tag used in protein expression and purification may be removed. The proteases used have high degree of specificity, such as thrombin, enterokinase, and TEV protease, so that only the targeted sequence may be cleaved. Complete inactivation of undesirable enzymatic activity or removal of unwanted proteins. For example, proteinase K, a broad-spectrum proteinase stable in urea and SDS, is often used in the preparation of nucleic acids to remove unwanted nuclease contaminants that may otherwise degrade the DNA or RNA. Partial inactivation, or changing the functionality, of specific protein. For example, treatment of DNA polymerase I with subtilisin yields the Klenow fragment, which retains its polymerase function but lacks 5'-exonuclease activity. Digestion of proteins in solution for proteome analysis by liquid chromatography-mass spectrometry (LC-MS). This may also be done by in-gel digestion of proteins after separation by gel electrophoresis for the identification by mass spectrometry. Analysis of the stability of folded domain under a wide range of conditions. Increasing success rate of crystallisation projects Production of digested protein used in growth media to culture bacteria and other organisms, e.g. tryptone in Lysogeny Broth.
The combination of heroin and xylazine produces a potentially more deadly high than heroin alone. Xylazine is also frequently found in "speedball", a mixture of a stimulant drug such as cocaine with a depressant drug such as heroin, morphine and/or fentanyl. As of 2012, causal factors underlying xylazine's increasing popularity were still unknown. As of 2022, more information on the distribution of xylazine in the body, physical symptoms, and factors predictive of chronic use was known: frequency of use depended on social or economic factors, as well as each user's subjective response to the drug's addictive properties. From November 2021 until August 2022, 80% of drug paraphernalia which tested positive for fentanyl at needle exchange programs in Maryland also contained xylazine. As of 2022, xylazine was almost invariably combined with opioids when used recreationally, and the drug produced a characteristic withdrawal syndrome which complicates treatment of addicted users. In April 2023, the Biden administration declared xylazine-laced fentanyl an official emerging drug threat to the nation, the first time such a label has been given. In 2022, the Drug Enforcement Administration (DEA) reported that 23% of seized fentanyl powder and 7% of fentanyl pills were found to have been adulterated with xylazine. In July 2023, the first death following xylazine use outside of North America was reported to have taken place in Solihull, England on May 22. A 43-year-old male was found dead at home with postmortem toxicology detecting heroin, cocaine, fentanyl and xylazine.
Sources: en.wikipedia.org
Major Brian James Dupree, Royal Army Physical Training Corps, Army Reserve, 551069. Major Robert George Fellows, The Rifles, 564703. Major Toby Christian Foster, The Rifles, 30039908. Lieutenant Colonel Christopher Simon Garrard, Corps of Royal Engineers, 24775389. Major Alex Jonathon Glynn, Royal Regiment of Artillery, 30050302. Major Jason Arthur Evan Groves, The Royal Welsh, 24870156. Major Kamal Gurung, The Queen's Gurkha Signals, 21169129. Major Alexander Roy Hamilton, , Corps of Royal Engineers, Army Reserve, 557167. Major Peter Anthony Harrison, , The Royal Logistic Corps, Army Reserve, 24859413. Major Steven Ross Duncan Maguire, The Royal Irish Regiment, 25232971. Bombardier (now Acting Sergeant) Alicia Rhiannon Martin, Royal Regiment of Artillery, 30177630. Major Neil Alexander McClelland, Scots Guards, 24867941. Major Christopher James Patrick Murphy, The Blues and Royals (Royal Horse Guards and 1st Dragoons), 30039546. Corporal Tonderai Ndlela, Adjutant General's Corps (Staff and Personnel Support Branch), 30145012. Lieutenant Colonel Christopher David Newton, Royal Regiment of Artillery, 24826197. Private Ernest Chinazor Okenyi, The Royal Logistic Corps, 30330523. Major Stacy Leanne Oliver, Royal Army Medical Corps, 30133469. Captain Pierre Andrew Ozanne, The Princess of Wales's Royal Regiment/The Ranger Regiment, 30277687. Lieutenant Colonel Daniel Sambrooke Proctor, Corps of Royal Electrical and Mechanical Engineers, 24781852. Staff Sergeant Matthew Francis Robinson, Corps of Royal Engineers, Army Reserve, 25099098.
To qualify for protection under the FCA, the whistleblower must demonstrate that they were engaged in FCA-protected activity and that the employer knew their activity was protected under the FCA, which presents a challenge for whistleblowers who merely report regulatory violations. To be protected under the FCA, they must reasonably believe the regulatory noncompliance has or will amount to fraud against the government, and they must put the employer on notice that their protected activity relates to the filing of false or fraudulent claims. Laboratory workers who merely report CLIA violations without tying the issues to Medicare or Medicaid reimbursement are unlikely to receive FCA whistleblower protection. From 2004-2005, approximately 460 patients Maryland General Hospital were tested for Hepatitis C and HIV with invalid controls. Follow-up retesting was not possible as many patients were unreachable due to being homeless. The incident prompted CAP to add whistleblower protections. In September 2015, a Theranos employee emailed a complaint to the Centers for Medicare and Medicaid Services (CMS) outlining regulatory noncompliance, which led to the company's exposure as a fraud and subsequent downfall.
== Cleavage & Deprotection == The Fmoc group is rapidly removed by base. Piperidine is usually preferred for Fmoc group removal as it forms a stable adduct with the dibenzofulvene byproduct, preventing it from reacting with the substrate.
These are made especially problematic due to the chemical solvents' ability to extract far greater amounts of the potentially toxic compounds than water. In the context of these concerns, the World Health Organization advises against the consumption of ethanolic and acetonic kavalactone extracts, and says that "products should be developed from water-based suspensions of kava". The government of Australia prohibits the sales of such kavalactone extracts, and only permits the sale of kava products in their natural form or produced with cold water.
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.